興科蓉醫藥(06833.HK)擬折讓約16.67%發行1.69億股 淨籌8406萬港元
格隆匯7月23日丨 興科蓉醫藥(06833.HK)公吿,於2021年7月23日,公司與認購方訂立認購協議,據此,公司有條件同意認購且公司有條件同意配發及發行合共1.69億股認購股份,認購價為每股認購股份0.5港元。認購價每股認購股份0.5港元較2021年7月23日(即認購協議日期)在聯交所所報收市價每股0.60港元折讓約16.67%。
認購股份相當於緊隨完成後經發行及配發認購股份擴大的已發行股約9.08%(假設於公吿日期至完成日期已發行股份總數概無任何變動,惟發行認購股份除外)。認購事項所得款項淨額合共將約為8406萬港元(經扣除認購事項的佣金及其他開支),淨髮行價為每股認購股份約0.497港元。
認購股份將根據一般授權發行及配發,毋須獲股東另行批准。公司擬將認購事項全部所得款項淨額約8406萬港元用作一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.